Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

Cardiovascular benefits of exogenous insulin.

Chaudhuri A, Dandona P, Fonseca V.

J Clin Endocrinol Metab. 2012 Sep;97(9):3079-91. doi: 10.1210/jc.2012-1112. Epub 2012 Jun 21. Review.

PMID:
22723317
3.

[Hypoglycemic therapy in heart disease patients with type 2 diabetes mellitus].

Cosmi F, Cosmi D.

G Ital Cardiol (Rome). 2010 Jun;11(6):460-6. Review. Italian.

PMID:
20922871
4.

Use of insulin to improve glycemic control in diabetes mellitus.

Dandona P, Chaudhuri A, Ghanim H, Mohanty P.

Cardiovasc Drugs Ther. 2008 Jun;22(3):241-51. doi: 10.1007/s10557-008-6101-3. Epub 2008 Mar 18. Review.

PMID:
18347965
5.

Reducing cardiovascular disease risk in patients with type 2 diabetes and concomitant macrovascular disease: can insulin be too much of a good thing?

Rensing KL, Reuwer AQ, Arsenault BJ, von der Thüsen JH, Hoekstra JB, Kastelein JJ, Twickler TB.

Diabetes Obes Metab. 2011 Dec;13(12):1073-87. doi: 10.1111/j.1463-1326.2011.01468.x. Review.

PMID:
21736687
6.

Safe and effective use of a glycemic control protocol for neonates in a cardiac ICU.

Hebson CL, Chanani NK, Rigby MR, Wolf MJ, Deshpande SR, Montegna LM, Maher KO.

Pediatr Crit Care Med. 2013 Mar;14(3):284-9. doi: 10.1097/PCC.0b013e31827200de.

PMID:
23392366
7.
8.

Mechanism by which hyperglycemia plays a role in the setting of acute cardiovascular illness.

Zarich SW.

Rev Cardiovasc Med. 2006;7 Suppl 2:S35-43. Review.

PMID:
17224876
9.

Insulin glargine: a systematic review of a long-acting insulin analogue.

Wang F, Carabino JM, Vergara CM.

Clin Ther. 2003 Jun;25(6):1541-77, discussion 1539-40. Review.

PMID:
12860485
10.

Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes.

Tandon N, Ali MK, Narayan KM.

Am J Cardiovasc Drugs. 2012 Feb 1;12(1):7-22. doi: 10.2165/11594650-000000000-00000. Review.

PMID:
22217193
11.

Potential role of salicylates in type 2 diabetes.

Rumore MM, Kim KS.

Ann Pharmacother. 2010 Jul-Aug;44(7-8):1207-21. doi: 10.1345/aph.1M483. Epub 2010 Jun 1. Review.

PMID:
20516365
12.

Achieve better glucose control for your hospitalized patients.

Woolever DR.

J Fam Pract. 2008 Dec;57(12):782-8. Review. No abstract available.

PMID:
19080760
13.
14.

Intensive glucose regulation in hyperglycemic acute coronary syndrome: results of the randomized BIOMarker study to identify the acute risk of a coronary syndrome-2 (BIOMArCS-2) glucose trial.

de Mulder M, Umans VA, Cornel JH, van der Zant FM, Stam F, Oemrawsingh RM, Akkerhuis KM, Boersma E.

JAMA Intern Med. 2013 Nov 11;173(20):1896-904. doi: 10.1001/jamainternmed.2013.10074.

PMID:
24018647
16.

Relevance of the vascular effects of insulin in the rationale of its therapeutical use.

Anfossi G, Russo I, Doronzo G, Trovati M.

Cardiovasc Hematol Disord Drug Targets. 2007 Dec;7(4):228-49. Review.

PMID:
18220724
17.

Intensive insulin regimens: evidence for benefit.

Bretzel RG.

Int J Obes Relat Metab Disord. 2004 Sep;28 Suppl 2:S8-13. Review.

PMID:
15306832
18.

Role of intravenous insulin therapy in critically ill patients.

Van den Berghe GH.

Endocr Pract. 2004 Mar-Apr;10 Suppl 2:17-20. Review.

PMID:
15251636
19.

Use of intensive insulin therapy for the management of glycemic control in hospitalized patients: a clinical practice guideline from the American College of Physicians.

Qaseem A, Humphrey LL, Chou R, Snow V, Shekelle P; Clinical Guidelines Committee of the American College of Physicians.

Ann Intern Med. 2011 Feb 15;154(4):260-7. doi: 10.7326/0003-4819-154-4-201102150-00007.

PMID:
21320941
20.

Glucagon like Peptide-1 and atherosclerosis.

Mita T, Watada H.

Cardiovasc Hematol Agents Med Chem. 2012 Dec;10(4):309-18. Review.

PMID:
22827292

Supplemental Content

Support Center